College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China.
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 639 LongMian road, NanJing, JiangSu 211198, PR China.
J Control Release. 2024 Jun;370:773-797. doi: 10.1016/j.jconrel.2024.05.007. Epub 2024 May 17.
The spleen, body's largest secondary lymphoid organ, is also a vital hematopoietic and immunological organ. It is regarded as one of the most significant organs in humans. As more researchers recognize the functions of the spleen, clinical methods for treating splenic diseases and spleen-targeted drug delivery systems to improve the efficacy of spleen-related therapies have gradually developed. Many modification strategies (size, charge, ligand, protein corona) and hitchhiking strategies (erythrocytes, neutrophils) of nanoparticles (NPs) have shown a significant increase in spleen targeting efficiency. However, most of the targeted drug therapy strategies for the spleen are to enhance or inhibit the immune function of the spleen to achieve therapeutic effects, and there are few studies on spleen-related diseases. In this review, we not only provide a detailed summary of the design rules for spleen-targeted drug delivery systems in recent years, but also introduce common spleen diseases (splenic tumors, splenic injuries, and splenomegaly) with the hopes of generating more ideas for future spleen research.
脾脏是人体最大的次级淋巴器官，也是一个重要的造血和免疫器官。它被认为是人体最重要的器官之一。随着越来越多的研究人员认识到脾脏的功能，治疗脾脏疾病的临床方法和针对脾脏的药物递送系统逐渐发展起来，以提高与脾脏相关的治疗效果。许多纳米颗粒（NPs）的修饰策略（大小、电荷、配体、蛋白冠）和搭便车策略（红细胞、中性粒细胞）都显示出显著提高脾脏靶向效率。然而，大多数针对脾脏的靶向药物治疗策略是增强或抑制脾脏的免疫功能以达到治疗效果，而针对脾脏相关疾病的研究较少。在这篇综述中，我们不仅详细总结了近年来脾脏靶向药物递送系统的设计规则，还介绍了常见的脾脏疾病（脾脏肿瘤、脾脏损伤和脾肿大），以期为未来的脾脏研究提供更多思路。
